

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 April 2020 (02.04.2020)



(10) International Publication Number
WO 2020/065064 A1

(51) International Patent Classification:

C07K 14/605 (2006.01) A61K 38/26 (2006.01)

(21) International Application Number:

PCT/EP2019/076305

(22) International Filing Date:

27 September 2019 (27.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18197755.4 28 September 2018 (28.09.2018) EP

(71) Applicant: **ZEALAND PHARMA A/S** [DK/DK]; Sydmarken 11, 2860 Søborg (DK).

(72) Inventors: **GIEHM, Lise**; c/o Zealand Pharma A/S, Sydmarken 11, 2860 Søborg (DK). **MELANDER, Claes**; c/o Zealand Pharma A/S, Sydmarken 11, 2860 Søborg (DK). **MØLLER, Eva Horn**; c/o Zealand Pharma A/S, Sydmarken 11, 2860 Søborg (DK).

(74) Agent: **MEWBURN ELLIS LLP**; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

(57) Abstract: Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described. Solid compositions comprising acetate salts of glucagon-like peptide 2 (GLP-2) analogues useful for making the liquid formulations are also described. The development of these liquid formulations is based on the finding that acetate present in the formulation that originates from the GLP-2 analogues has an effect on the viscosity of the formulation, that during long term storage at 2-8°C of GLP-2 analogues, the concentration dependence for covalent oligomer formation is inversely dependent on increasing concentration of the GLP-2 analogue, and that GLP-2 analogues used in the formulations are not compatible with phosphate buffer commonly used in the prior art to reconstituted powdered or lyophilized GLP-2 compositions.



WO 2020/065064 A1